Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 5/20 | 0.41 |
| ▸ | DRD2 | P14416 | 7/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233319 | 0.86 | NPC1 (0.42) | NPC1RAB9AATMCCR1DRD2 | |
| SCHEMBL4745106 | 0.79 | CYP2D6 (0.47) | DRD2CYP2D6MAPK1ALDH1A1CYP3A4 | |
| SCHEMBL12726887 | 0.72 | OPRL1 (0.61) | DRD2 | |
| SCHEMBL6023280 | 0.67 | NPC1 (0.54) | NPC1RAB9AATMALDH1A1 | |
| SCHEMBL706443 | 0.67 | HDAC1 (0.58) | NPC1RAB9AATMMAPK1 | |
| SCHEMBL10123127 | 0.67 | RAB9A (0.54) | NPC1RAB9AATMALDH1A1 | |
| SCHEMBL28360034 | 0.66 | NPC1 (0.52) | NPC1RAB9AATMCYP3A4 | |
| SCHEMBL4240834 | 0.66 | OGG1 (0.53) | NPC1RAB9AATMALDH1A1 | |
| SCHEMBL3750397 | 0.66 | POLB (0.54) | NPC1RAB9AATMALDH1A1 | |
| SCHEMBL3757683 | 0.66 | NPC1 (0.52) | NPC1RAB9AATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | NPC1 2338/4885RAB9A 2492/4885ATM 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.